###### Strengths and limitations of this study

-   The strengths of our study include the high participation rates and the use of spirometry for evaluating the exact prevalence of airflow limitation in both 1967 and 2012 surveys.

-   One limitation was the difference in the instruments used for spirometry: a dry wedge bellows spirometer in 1967 versus a more sophisticated instrument in 2012.

-   Another limitation was the possible decrease in airflow limitation due to the bronchodilators that have been used as standard therapies for chronic obstructive pulmonary disease and asthma over the last decade in our country.

Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD), which is characterised by persistent respiratory symptoms and airflow limitation defined by postbronchodilator spirometry, is a major threat to the health of the respiratory system. COPD is composed of a mixture of small airway disease (eg, obstructive bronchiolitis) and parenchymal destruction (emphysema) and can lead to acute exacerbation of respiratory symptoms and airway function, ultimately progressing to respiratory failure.[@R1] In addition, COPD poses a great burden in terms of morbidity and premature mortality as well as in healthcare expenditures worldwide.[@R2] Prebronchodilator airflow limitation, which include chronic obstructive ventilatory disorders such as COPD, asthma and bronchiectasis, is a well-used outcome in the epidemiological study without postbronchodilator spirometry. Therefore, it would be clinically and epidemiologically valuable to clarify the trends in the prevalence of airflow limitation and in the influence of risk factors on airflow limitation in individual communities.

A previous literature-based meta-analysis estimated that the prevalence of airflow limitation increased over two decades in both developed and developing regions, but these estimations were based on a statistical model.[@R3] Few studies have addressed the trends in the prevalence of airflow limitation over time based on the data from repeated community-based surveys, although the nationwide surveys in the USA showed a decreasing trend in the prevalence of airflow limitation.[@R4] Tobacco smoke, indoor and outdoor air pollutants and occupational dust have been acknowledged as major risk factors for airflow limitation along with genetic factors such as alpha~1~-antitrypsin deficiency,[@R5] but there has been no survey assessing the associations of risk factors with the prevalence of airflow limitation in a time series manner. In recent decades, reduction of environmental pollution in the atmosphere and workplace and the reduction in smoking prevalence[@R6] may have affected the influence of these risk factors on airflow limitation.

The purpose of the present study was to evaluate trends in the prevalence of airflow limitation in Japan from 1967 to 2012 using two serial cross-sectional surveys concerning different generations from a long-term community-based study, the Hisayama Study, with high participation rates and a consistent spirometric definition of airflow limitation. In addition, the magnitudes of the association of risk factors with airflow limitation were compared between surveys.

Methods {#s2}
=======

Study population {#s2a}
----------------

Since 1961, a population-based prospective study has been longitudinally conducted to investigate the distributions and associations of lifestyle-related diseases and their risk factors in the town of Hisayama, Japan. Details of this cohort study have been described elsewhere.[@R11] As part of an annual health examination, two serial cross-sectional surveys of airflow limitation with spirometry were performed in 1967 and 2012. In 1967, a total of 1973 residents aged ≥40 years (88.0% of the whole population in this age group) consented to participate in an examination and underwent a comprehensive health assessment. Among them, 129 subjects who were either unable or unwilling to submit to a measurement of pulmonary function and 2 subjects in whom spirometric measurements were performed incorrectly were excluded. The remaining 1842 subjects (824 men and 1018 women) with successfully measured pulmonary function were enrolled in the present study. Similarly, in 2012, 3396 subjects participated in a health examination (participation rate: 72.6%). After excluding six subjects who refused to participate in the epidemiological research and 357 subjects who were either unable or unwilling to submit to spirometric measurement, 3033 subjects (1340 men and 1693 women) with proper spirometric measurements were enrolled in the study (online [supplementary figure E1](#SP1){ref-type="supplementary-material"}).
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Assessment and definition of airflow limitation {#s2b}
-----------------------------------------------

A dry wedge bellows spirometer was used in 1967 to obtain volume--time curves. Participants underwent spirometry several times until valid curves were obtained. Pulmonary physicians graphically evaluated and scrutinised the figures and obtained the values of forced expiratory volume in 1 s (FEV~1~), forced vital capacity (FVC) and FEV~1~/FVC. In the 2012 survey, spirometry was performed in line with the guidelines of the Japanese Respiratory Society (JRS).[@R12] Two to four measurements were performed using a CHESTGRAPH HI-105 electronic spirometer (Chest MI, Tokyo), in order to obtain satisfactory flow-volume loops. Pulmonary physicians visually assessed the quality of the manoeuvres and chose the finest loop, showing the highest sum of FEV~1~ and FVC. FVC, FEV~1~ and FEV~1~/FVC were obtained from the selected curve. Bronchodilators were not used for any of the surveys.

Airflow limitation was pathophysiologically assessed with spirometry and without any radiological measurements or clinical symptoms. There are two major worldwide criteria for the definition of airflow limitation: the modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria with a fixed cut-off of FEV~1~/FVC[@R13] and the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria using age-specific, sex-specific and height-specific lower limits of normal (LLNs) for the cut-off of FEV~1~/FVC.[@R14] We employed both the GOLD criteria and the ATS/ERS criteria. When calculating LLN, we used the reference equations for the Japanese population that were reported by the Clinical Pulmonary Functions Committee of the JRS in 2014.[@R15] Those equations were derived using the lambda, mu and sigma method employed by the ERS Global Lung Function Initiative (GLI) Task Force, since the GLI reference group did not include Japanese subjects.[@R15] The GOLD criteria-based airflow limitation was defined as FEV~1~/FVC \<70%. We also used a modified definition of airflow limitation (ie, FEV~1~/FVC \<67%), because the dry wedge bellows spirometer has been reported to yield values 2%--3% lower than those measured by a water-sealed spirometer or an electronic spirometer.[@R17] Among participants with airflow limitation, the severity was defined using the predicted FEV~1~ value for a person of the same age, sex and height using the equation for the Japanese population[@R15] as follows: mild: FEV~1~ ≥80% of predicted; moderate: 50% ≤ FEV~1~ \<80% of predicted; severe and very severe: FEV~1~ \<50% of predicted. The ATS/ERS criteria-based airflow limitation was defined as FEV~1~/FVC \<the fifth percentile (LLN), and the severity of airflow limitation was defined as follows: mild: FEV~1~ ≥70% predicted; moderate and moderately severe: 50% ≤FEV~1~\<70% predicted; and severe and very severe: FEV~1~ \<50% predicted. Regarding the ATS/ERS criteria-based airflow limitation, we also calculated LLN using the reference equations for the Japanese population that were reported by the ERS GLI Task Force in 2012.[@R16]

Clinical evaluation and laboratory measurements {#s2c}
-----------------------------------------------

Each participant completed a self-administered questionnaire covering smoking habits, alcohol intake, medical history and antihypertensive treatments. Smoking habits were categorised as never smokers or current/former smokers since airflow limitation could persist even after cessation of smoking. Alcohol drinking was defined as current or not. Body height and weight were measured in light clothing without shoes, and body mass index (BMI; kg/m^2^) was calculated. Overweight and underweight were defined as BMI ≥25.0 kg/m^2^ and BMI \<18.5 kg/m^2^, respectively. Blood pressure was measured three times using a mercury sphygmomanometer in 1967 and an automated sphygmomanometer (BP-203 RVIIIB; Omron Healthcare, Kyoto) in 2012 in a sitting position after rest for at least 5 min; the average values were used in the analyses. Hypertension was defined as a systolic blood pressure ≥140 mm Hg, a diastolic blood pressure ≥90 mm Hg or current treatment with antihypertensive agents.

Statistical analysis {#s2d}
--------------------

The SAS software package V.9.4 was used to perform all statistical analyses. Baseline characteristics were shown as age-adjusted values by sex and by survey year using the analysis of covariance (ANCOVA) for continuous variables or by the direct method using the age distribution of the 1985 Japanese population as a standard.[@R19] They were compared between survey years using an ANCOVA, a Cochran-Mantel-Haenszel test or a logistic regression model. The sex-specific prevalence of airflow limitation was estimated separately for each age group (40--49, 50--59, 60--69 and 70+ years) and as a whole adjusting for age by the direct method using the same standard population. The linear trend of airflow limitation across age groups in each survey year was tested using a logistic regression model. The same model was used for the test of secular trends in sex-specific and age-standardised prevalence of airflow limitation from 1967 to 2012. Among residents with airflow limitation, the sex-specific and age-standardised distribution of its severity was compared between survey years using an ordinal logistic regression model. The associations of potential risk factors with airflow limitation were estimated as adjusted ORs with 95% CIs for each survey year by using multivariable-adjusted logistic regression models, wherein adjustment was made for sex, age, smoking habits, overweight, underweight, hypertension and living alone that were associated with airflow limitation or COPD in previous reports.[@R1] Multivariable-adjusted ORs with 95% CIs were calculated using data of subjects with no missing data (proportion of subjects excluded: 2.1% in 1967 and 0.07% in 2012). We tested whether these associations were changed over decades by including the interactions of risk factors and the survey years in the relevant statistical models. The contribution of each risk factor to airflow limitation was estimated as a population attributable fraction (PAF) in each survey using the multivariable-adjusted OR of each risk factor and its frequency among cases,[@R23] which represents the proportional reduction in population that would occur if each risk factor was eliminated. The 95% CIs of the PAFs were estimated in accordance with Greenland's method.[@R24]

As described above, the analysis was also performed using the ATS/ERS criteria with the JRS or GLI reference equations for each survey year. Another sensitivity analysis was performed with the modified definition of airflow limitation, which was FEV~1~/FVC of \<67%. A two-sided value of p\<0.05 was considered to indicate statistical significance.

Participant involvement {#s2e}
-----------------------

There was no direct patient involvement in the development, design or conduct of the study.

Ethical considerations {#s2f}
----------------------

Written or oral informed consent was obtained from all the participants. In addition, we are applying an opt-out methodology to announce that the study is ongoing and to provide the opportunity of refusal through the official website according to the ethical guidelines for medical and health research involving human subjects in Japan.[@R25]

Results {#s3}
=======

Demographic and clinical characteristics {#s3a}
----------------------------------------

The demographic and clinical characteristics in 1967 and 2012 are summarised by sex in [table 1](#T1){ref-type="table"}, in which the mean values and the frequencies were adjusted for age. In both sexes, subjects in 2012 were older than those in 1967. The mean values of height, weight and BMI were higher in 2012 than 1967. The frequencies of drinking habits and living alone also increased over 45 years. The prevalence of hypertension decreased with time. For smoking habits (current or ever smoking), there was a downward trend in men and an upward trend in women, although the frequency of ever smokers significantly increased in both sexes (from 11.5% in 1967 to 44.1% in 2012 for men, and from 1.7% in 1967 to 11.6% in 2012 for women; p\<0.001 in both sexes).

###### 

Age-adjusted mean values or frequencies of demographic and clinical characteristics in 1967 and 2012 by sex

  Variables                          Men            Women                                                  
  ---------------------------------- -------------- -------------- --------- -------------- -------------- ---------
  Age (years)                        55.0 (0.40)    63.1 (0.32)    \<0.001   55.5 (0.37)    62.9 (0.29)    \<0.001
  Height (cm)                        158 (0.21)     166 (0.16)     \<0.001   146 (0.17)     153 (0.13)     \<0.001
  Weight (kg)                        53.2 (0.32)    65.8 (0.25)    \<0.001   47.4 (0.27)    53.6 (0.21)    \<0.001
  BMI (kg/m^2^)                      21.4 (0.10)    23.8 (0.08)    \<0.001   22.3 (0.11)    22.8 (0.09)    \<0.001
  Degree of fatness                                                                                        
   Overweight (%)                    7.6            31.5           \<0.001   17.0           22.0           0.001
   Normal weight (%)                 84.9           64.6           72.4      67.6                          
   Underweight (%)                   7.5            3.9            10.6      10.5                          
  Smoking habit (current/ever) (%)   83.6           79.8           0.08      13.9           20.6           0.003
   Current smoker (%)                72.1           35.7           \<0.001   12.2           9.0            \<0.001
   Ever smoker (%)                   11.5           44.1           \<0.001   1.7            11.6           \<0.001
  Alcohol intake (%)                 63.3           74.7           \<0.001   4.1            40.1           \<0.001
  Hypertension (%)                   57.3           47.7           \<0.001   53.0           33.8           \<0.001
  Systolic blood pressure (mm Hg)    147.0 (0.78)   130.7 (0.61)   \<0.001   145.7 (0.65)   125.4 (0.50)   \<0.001
  Diastolic blood pressure (mm Hg)   86.4 (0.44)    79.8 (0.34)    \<0.001   83.8 (0.37)    74.0 (0.28)    \<0.001
  Antihypertensive medication (%)    13.6           29.3           \<0.001   15.0           21.8           \<0.001
  Living alone (%)                   1.3            4.5            \<0.001   2.5            5.4            0.002

Age is given as the mean plus SE. Other values are given as the age-adjusted mean (if appropriate) with SEs in brackets for continuous variables and as age-adjusted percentages for dichotomised or categorical variables. P values denote the statistical significance of the difference in each variable between 1967 and 2012. Overweight was defined as a BMI ≥25.0 kg/m^2^. Underweight was defined as a BMI \<18.5 kg/m^2^. Smoking habits were categorised as never smokers or current/former smokers. Alcohol intake was defined as current or not. Hypertension was defined as blood pressure ≥140/90 mm Hg and/or current use of antihypertensive agents. Numbers of subjects with missing data were as follows: alcohol intake: 20, hypertension: 4, antihypertensive medication: 10 and living alone: 9 in men in 1967; living alone: 1 in men in 2012; smoking habit: 2, alcohol intake: 42, hypertension: 3, antihypertensive medication: 5 and living alone: 25 in women in 1967; no missing data in women in 2012.

BMI, body mass index.

Trends in the prevalence of airflow limitation {#s3b}
----------------------------------------------

Among the 1842 and 3033 survey subjects in 1967 and 2012, 401 and 524 subjects had airflow limitation, respectively. The age-standardised prevalence decreased over the intervening decades (from 26.3% to 16.1% in men and 19.8% to 10.5% in women) ([figure 1](#F1){ref-type="fig"}). Almost all age groups in both sexes, with the exception of 40--49 years in women, showed significant downward trends in the age-specific prevalence from 1967 to 2012 ([figure 2](#F2){ref-type="fig"}). The prevalence of airflow limitation increased with age in both 1967 and 2012 (all p\<0.001 for trend). As shown in [figure 3](#F3){ref-type="fig"}, there was a significant shift in the distribution of severity of airflow limitation in both men and women with airflow limitation; the proportions of moderate and severe/very severe airflow limitation decreased over time, while the proportion of mild airflow limitation increased (p\<0.001 for difference in both sexes). The results of the analyses were not substantially changed according to whether the ATS/ERS criteria with the JRS reference equations (online [supplementary figure E2--4](#SP1){ref-type="supplementary-material"}), the GLI reference equations (online [supplementary figure E5--7](#SP1){ref-type="supplementary-material"}) or the modified definition of airflow limitation (ie, FEV~1~/FVC \<67%) from 1967 (online [supplementary figure E8-10](#SP1){ref-type="supplementary-material"}) was used.

![Trends in the age-adjusted prevalence of airflow limitation in 1967 and 2012 by sex. Vertical bars indicate 95% CIs. \*P\<0.001 versus 1967. Airflow limitation was defined as forced expiratory volume in 1 s/forced vital capacity \<70% according to the Global Initiative for Chronic Obstructive Lung Disease criteria.](bmjopen-2018-023673f01){#F1}

![Trends in the prevalence of airflow limitation according to age groups in 1967 and 2012 by sex. \*P\<0.05, ^†^p\<0.01 versus 1967, ^‡^p for trend \<0.01. Airflow limitation was defined as forced expiratory volume in 1 s/forced vital capacity \<70% according to the Global Initiative for Chronic Obstructive Lung Disease criteria.](bmjopen-2018-023673f02){#F2}

![Trends in the age-adjusted prevalence of airflow limitation according to severity in 1967 and 2012 by sex. Airflow limitation was defined as forced expiratory volume in 1 s/forced vital capacity \<70% according to the Global Initiative for Chronic Obstructive Lung Disease criteria.](bmjopen-2018-023673f03){#F3}

Trends in the associations of risk factors with airflow limitation {#s3c}
------------------------------------------------------------------

There was a significant positive association of smoking with airflow limitation in both surveys (OR=1.63 (95% CI 1.19 to 2.24), p=0.003 in 1967; OR=2.26 (95% CI 1.72 to 2.99), p\<0.001 in 2012) ([figure 4](#F4){ref-type="fig"}). In comparison, there was a stronger association between smoking and airflow limitation in 2012 than in 1967 (p=0.007 for interaction). Consequently, the contribution of smoking to the estimated proportion of cases with airflow limitation---that is, PAF---was 21.1% in 1967 and 33.5% in 2012 (a 1.5-fold increase). Overweight was negatively associated with airflow limitation in both surveys (OR=0.65 (95% CI 0.42 to 0.98), p=0.04 in 1967; OR=0.66 (95% CI 0.52 to 0.85), p=0.001 in 2012), and there was no statistically significant difference between them (p=0.84 for interaction). Nevertheless, due to the twofold elevation in the proportion of overweight from 13.0% in 1967 to 26.7% in 2012, the potential of overweight for reducing the proportion of airflow limitation (PAF) was greater in 2012 than in 1967 (−4.1% in 1967 to −10.3% in 2012). For the associations of sex (men vs women) with airflow limitation, we found a significant difference between survey years, although neither association reached statistical significance. The other variables were not associated with airflow limitation and made no significant contributions to the PAF. In the sex-specific analysis, the influence of each risk factor on airflow limitation was substantially similar between sexes (all p\>0.06 for heterogeneity), except for underweight in 1967 (p=0.002 for heterogeneity) (online [supplementary figure E11](#SP1){ref-type="supplementary-material"}).

![Multivariate-adjusted ORs and PAFs of risk factors for airflow limitation in 1967 and 2012. Airflow limitation was defined as forced expiratory volume in 1 s/forced vital capacity \<70%. Adjustments were made for sex, age, smoking habits, overweight\*, underweight\*, hypertension and living alone. Horizontal bars indicate 95% CIs. \*For the analysis of overweight and underweight, the normal weight group was used as the reference group. PAF, population attributable fraction; RF, risk factor.](bmjopen-2018-023673f04){#F4}

Discussion {#s4}
==========

The present comparison of the prevalence of airflow limitation based on the GOLD criteria in Japan revealed a significant reduction from 1967 to 2012, consistently across age-groups in both men and women. Among participants with airflow limitation, the proportion with a moderate to severe level of the disorder decreased remarkably. Similar findings were observed with the ATS/ERS criteria. Moreover, both the relative association between smoking and airflow limitation and the PAF of smoking were compared and found to be stronger in 2012 than in 1967. This is the first study to evaluate trends in the prevalence of airflow limitation and in the influence of its risk factors in an Asian population on the basis of the data from repeated community-based surveys.

Epidemiological findings in regard to trends in the prevalence of airflow limitation are very limited. A literature-based meta-analysis of cross-sectional spirometric surveys showed that there was an increase in the prevalence of airflow limitation from the 1990s to 2010s in both developed and developing regions.[@R3] However, these estimations were calculated by using a statistical model on the basis of demographic changes over time. However, the results from the repeated nationwide National Health and Nutrition Examination Surveys demonstrated that there was a significant decrease in the prevalence of airflow limitation in the USA from 1988--1994 to 2007--2010, although it barely changed from 1971--1975 to 1988--1994.[@R4] This finding was in accord with ours. The reduction of environmental pollution in both the atmosphere and workplace and the reduction in the smoking frequency may have decreased the prevalence of airflow limitation in the USA as well as in our population.[@R6]

Previous studies estimated the prevalence of airflow limitation in Japan in the 2000s as 16.2%--16.4% among men and 5.0%--5.8% among women.[@R27] The former range was similar to that in 2012 in the present study, while the latter was twofold lower. The discrepancy may be due to the difference in the participation rate, which would likely lead to a selection bias; the participation rate in our study was over threefold higher than those in the preceding studies. The prevalence of airflow limitation determined using the GOLD criteria has been reported to be higher than that based on the ATS/ERS criteria in elderly populations,[@R4] which was consistent with our study. However, other than ours, there has been no study estimating the prevalence of airflow limitation in Japan using the ATS/ERS criteria, and thus further studies are needed.

In the present study, the potentiating effects of smoking on airflow limitation were more pronounced in 2012 than in 1967. Cigarette smoking and chronic inhalational exposure to a polluted atmosphere both lead to COPD by the same mechanism, that is, hazardous particles penetrating deep into the respiratory tract and eliciting neutrophilic inflammation and oxidative stress.[@R30] However, environmental, occupational and household exposure to hazardous pollutants has been steadily attenuated over the last several decades. This reduction in exposure to atmospheric pollutants could have increased the relative influence of smoking in recent years.[@R31] In turn, the prevention of tobacco use and the promotion of smoking cessation have become increasingly important public health concerns in order to prevent airflow limitation and COPD.

The present study showed that overweight was inversely associated with airflow limitation both in 1967 and 2012. Previous observational studies demonstrated that higher BMI was associated with lower FVC and therefore with higher FEV~1~/FVC,[@R20] which probably reflected the decrease in excursion of the thoracic cage due to intra-abdominal and subpleural fat deposition.[@R33] Our present findings may also be explained by reverse causality; weight loss commonly occurs in COPD patients via muscle wasting and elevated energy metabolism.[@R21] The weaker association and smaller PAF among women than among men in 2012 can be explained by the relatively small number of female participants with airflow limitation. There was no evidence of a significant association between underweight and airflow limitation in either survey, but the influence of underweight on the airflow limitation was different between the sexes. The underlying explanation for this heterogeneity was unclear. It may merely reflect the play of chance.

In the present study, the magnitude of the association between male sex and the airflow limitation in 2012 was significantly greater than that in 1967, although the OR for each survey did not reach statistical significance. This heterogeneity may have been caused by residual confounding due to the greater amount and duration of tobacco smoking in men than women, considering the fact that the influence of smoking habits increased with time, as mentioned above. Nevertheless, based on the current evidence, it remains controversial whether the male sex is a risk factor for airflow limitation.[@R34] Further evaluation of this matter is warranted.

The strengths of our study include the high participation rates and the use of spirometry for evaluating the exact prevalence of airflow limitation in both surveys. However, some potential limitations should be noted. First, there was a difference in the instruments used for spirometry: a dry wedge bellows spirometer in 1967 versus a more sophisticated instrument in 2012. This limitation could have led to an overestimation of the prevalence of airflow limitation in 1967, since the dry wedge bellows spirometer has been reported to generate 2%--3% smaller FEV~1~/FVC values compared with the instrument used in 2012.[@R17] However, several other studies have reported that the dry wedge bellows spirometer exhibited comparable reliability to more sophisticated instruments.[@R38] Additionally, the sensitivity analyses using the 3% lower cut-off value for FEV~1~/FVC in 1967 showed similar results. Hence, this potential bias did not appear to have affected the present results. Second, there was a possibility of decrease in airflow limitation due to the bronchodilators, such as short-acting β2 agonist, short-acting muscarinic antagonist, long-acting β2 agonist (LABA), long-acting muscarinic antagonist (LAMA), inhaled corticosteroids/LABA, LABA/LAMA and xanthine, that have been used as standard therapies for COPD and asthma over the last decade in our country.[@R42] However, the proportion of subjects who used bronchodilators was only 2.6% (n=80) in 2012, and thus the decrease in the prevalence of airflow limitation was unlikely by virtue of the effects of these medications. Third, we did not have access to a pulmonary function test with assessment of airflow reversibility or postbronchodilator FEV~1~/FVC; some of the individuals with airflow limitation might have had chronic obstructive ventilatory disorders such as asthma rather than COPD. However, this limitation would not have changed our conclusion, because the prevalence of airflow limitation decreased in the present study despite the increasing trend in the prevalence of asthma in Japan.[@R44] Fourth, airflow limitation could also include a restrictive ventilatory disorder associated with an obstructive disorder, such as combined pulmonary fibrosis and emphysema (CPFE). However, in a recent epidemiological study, subjects with CPFE were found to make up only 5%--10% of total COPD cases.[@R45] Thus, this limitation may not have altered our conclusions. Fifth, airflow limitation could include several types of obstructive disorders, and thus we should be cautious about concluding that individual risk factors affect all of the diseases providing airflow limitation. Lastly, we were unable to investigate the effects of intensity or duration of smoking on airflow limitation due to lack of data concerning the number of pack years of cigarette smoking in 1967. However, in Japan, it has been reported that the number of cigarettes smoked per day has remained unchanged among smokers of both sexes (about 20 per day in men and about 15 per day in women) since the 1950s.[@R46] In addition, the frequency of ever smokers who stopped smoking significantly increased in both sexes in the present study. Thus, we believe that the intensity or duration of smoking did not increase from 1967 to 2012.

In conclusion, over the past half century, the prevalence of airflow limitation that included COPD as well as other chronic obstructive ventilatory disorders has decreased significantly among the general Japanese population. However, more than 10% of men and women aged 40 years or older still exhibit airflow limitation. With respect to risk factors, the contribution of smoking to the occurrence of airflow limitation has become more pronounced over the previous five decades, which we speculated as a result of a reduction in the occupational exposures to indoor and outdoor air pollution. To accelerate the prevention of airflow limitation, therefore, further public efforts towards smoking cessation are mandatory.
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